Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142571 · ClinicalTrials.gov registry record · Phase 3
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
A Phase 3 study of Sarcoma,Soft Tissue, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00142571: Completed Phase 3 study of Sarcoma,Soft Tissue, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00142571 is a Phase 3 study of Sarcoma,Soft Tissue that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 120 participants, above the 68-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142571, a Phase 3 study of Sarcoma,Soft Tissue, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
What the finished NCT00142571 record still lists
NCT00142571 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 68-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Sarcoma,Soft Tissue appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00142571 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00142571 about?
NCT00142571 is a clinical study titled "Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma". The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.
What is the current status of trial NCT00142571?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2003-01. Estimated completion is 2007-09.
What conditions does trial NCT00142571 study?
This clinical trial studies the following conditions: Sarcoma,Soft Tissue.
What interventions are being tested in trial NCT00142571?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00142571?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142571 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma,Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00142571's enrollment target sits among peer trials
120 3rd of 12 higher than 10 of 12 other Sarcoma,Soft Tissue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma,Soft Tissue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia